|
| 37475136 | A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial. | Cancer Res Treat | 2024 |
| 38062732 | Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. | Thyroid | 2024 |
| 37699162 | Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial. | J Clin Oncol | 2024 |
| 35976444 | Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance. | J Cancer Res Clin Oncol | 2023 |
| 37489066 | Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma. | Cancer Med | 2023 |
| 37712875 | A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. | Cancer Res Commun | 2023 |
| 37828867 | Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma. | Head Neck | 2023 |
| 37880430 | Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. | Insights Imaging | 2023 |
| 37643133 | A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. | Clin Cancer Res | 2023 |
| 37675597 | Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort study. | Thorac Cancer | 2023 |
| 37870969 | Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer. | N Engl J Med | 2023 |
| 37220755 | Antibiotic prescription patterns during last days of hospitalized patients with advanced cancer: the role of palliative care consultation. | J Antimicrob Chemother | 2023 |
| 37218137 | Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. | Cancer Res Treat | 2023 |
| 36947985 | Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study. | ESMO Open | 2023 |
| 37385153 | Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. | ESMO Open | 2023 |
| 37337807 | Ethical Issues Referred to Clinical Ethics Support at a University Hospital in Korea: Three-Year Experience After Enforcement of Life-Sustaining Treatment Decisions Act. | J Korean Med Sci | 2023 |
| 37272558 | Moral Distress Regarding End-of-Life Care Among Healthcare Personnel in Korean University Hospitals: Features and Differences Between Physicians and Nurses. | J Korean Med Sci | 2023 |
| 37365741 | Changes in the Utilization of Health Care Services by Cancer Patients during the COVID-19 Pandemic. | Yonsei Med J | 2023 |
| 37357950 | A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer. | Int J Cancer | 2023 |
| 37162306 | Use of high-flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life. | Cancer Med | 2023 |
| 36720658 | Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. | Eur Urol Oncol | 2023 |
| 36547689 | Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. | J Cancer Res Clin Oncol | 2023 |
| 36915254 | Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer. | Cancer Res Treat | 2023 |
| 36436443 | The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines. | Transl Oncol | 2023 |
| 36397238 | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03). | Cancer Res Treat | 2023 |
| 36833145 | Challenges in Care for Non-COVID-19 Patients with Severe Chronic Illnesses during COVID-19 Pandemic: A Qualitative Study of Healthcare Providers Working around Acute Care Hospitals in South Korea. | Healthcare (Basel) | 2023 |
| 36672420 | Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01). | Cancers (Basel) | 2023 |
| 33940786 | Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer. | Cancer Res Treat | 2022 |
| 37674892 | Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement. | J Hosp Palliat Care | 2022 |
| 37674665 | Impact of COVID-19 on the End-of-Life Care of Cancer Patients Who Died in a Korean Tertiary Hospital: A Retrospective Study. | J Hosp Palliat Care | 2022 |
| 35437962 | Hospice-Palliative Medicine as a Model of Value-Based Healthcare. | J Korean Med Sci | 2022 |
| 35403447 | A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60â¿¿mg Per Day Compared with the Cabozantinib Capsule at 140â¿¿mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. | Thyroid | 2022 |
| 35538696 | The impact of COVID-19 on cancer care in a tertiary hospital in Korea: possible collateral damage to emergency care. | Epidemiol Health | 2022 |
| 35344842 | Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. | Curr Probl Cancer | 2022 |
| 35668487 | Aggressiveness of care in the last days of life in the emergency department of a tertiary hospital in Korea. | BMC Palliat Care | 2022 |
| 35760396 | The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea. | Epidemiol Health | 2022 |
| 35819451 | A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11). | Clin Cancer Res | 2022 |
| 35693980 | Comparable Clinical Outcome Using Small or Large Gross Tumor Volume-to-Clinical Target Volume Margin Expansion in Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. | J Oncol | 2022 |
| 36606303 | Feasibility and safety of neck level IB-sparing radiotherapy in nasopharyngeal cancer: a long-term single institution analysis. | Radiat Oncol J | 2022 |
| 36424671 | The impact of palliative care consultation on reducing antibiotic overuse in hospitalized patients with terminal cancer at the end of life: a propensity score-weighting study. | J Antimicrob Chemother | 2022 |
| 35970031 | TCF1<sup>+</sup>PD-1<sup>+</sup> tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer. | Eur J Cancer | 2022 |
| 35869130 | Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis. | Sci Rep | 2022 |
| 35985251 | Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure. | Eur J Cancer | 2022 |
| 36259380 | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. | Cancer | 2022 |
| 36320008 | High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration. | BMC Cancer | 2022 |
| 35217573 | Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. | J Immunother Cancer | 2022 |
| 35026411 | Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. | Ann Oncol | 2022 |
| 34929077 | Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). | Korean J Intern Med | 2022 |
| 35194143 | Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer. | Sci Rep | 2022 |
| 33940788 | Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01). | Cancer Res Treat | 2022 |